顺铂和奈达铂同步质子重离子放疗治疗鼻咽恶性肿瘤的临床疗效比较  

Comparison of Clinical Efficacy of Simultaneous Proton and Heavy Ion Radiotherapy Between Cisplatin and Nedaplatin in the Treatment of Nasopharyngeal Malignant Tumor

作　　者：许蒙 翟青 XU Meng;ZHAI Qing(Dept. of Pharmacy, Fudan University Shanghai Cancer Center, Dept. of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China;Dept. of Pharmacy, Shanghai Proton and Heavy Ion Center, Shanghai 201315, China;Shanghai Engineering Research Center of Proton and Heavy Ion Radiation Therapy, Shanghai 201315, China)

机构地区：[1]复旦大学附属肿瘤医院药剂科,复旦大学上海医学院肿瘤学系,上海200032 [2]上海市质子重离子医院药剂科,上海201315 [3]上海质子重离子放射治疗工程技术研究中心,上海201315

出　　处：《中国医院用药评价与分析》2020年第8期910-913,共4页Evaluation and Analysis of Drug-use in Hospitals of China

基　　金：上海市卫生健康委员会重要薄弱学科建设计划项目(No.2016ZB0301-02)。

摘　　要：目的:以奈达铂取代顺铂进行单周同步质子重离子放疗方案,从疗效、不良反应及药物经济学方面比较其与顺铂同步质子重离子放疗方案治疗鼻咽恶性肿瘤的区别。方法:收集2017年1月至2019年6月复旦大学附属肿瘤医院质子重离子中心接受顺铂同步质子重离子放疗(顺铂组,46例)或奈达铂同步质子重离子放疗(奈达铂组,45例)治疗的鼻咽恶性肿瘤患者91例进行回顾性分析,比较其疗效、不良反应及成本的差异。结果:顺铂组患者的有效率、临床受益率分别为73.91%(34/46)、93.48%(43/46),奈达铂组患者的有效率、临床受益率分别为75.56%(34/45)、93.33%(42/45);两组患者有效率和临床受益率的差异无统计学意义(P>0.05)。但顺铂组患者血红蛋白降低、电解质紊乱、肾损伤和恶心呕吐的发生率明显高于奈达铂组,差异均有统计学意义(P<0.05)。顺铂组患者单纯化疗药费用明显低于奈达铂组,差异有统计学意义(P<0.05);但两组患者总成本的差异无统计学意义(P>0.05)。结论:顺铂与奈达铂同步质子重离子放疗治疗鼻咽恶性肿瘤的近期疗效和总成本相当,但奈达铂的不良反应明显更少。OBJECTIVE:Replacing cisplatin by nedaplatin for single-week simultaneous proton and heavy ion radiotherapy,so as to compare with cisplatin for simultaneous proton and heavy ion radiotherapy in the treatment of nasopharyngeal malignant tumor in terms of efficacy,adverse drug reactions and pharmacoeconomics.METHODS:91 patients with nasopharyngeal malignant tumor receiving simultaneous proton and heavy ion radiotherapy of cisplatin(cisplatin group,46 cases)and nedaplatin(nedaplatin group,45 cases)admitted into Fudan University Shanghai Cancer Certer Proton and Heavy Ion Center from Jan.2017 to Jun.2019 were collected,differences in efficacy,adverse drug reactions and costs were compared between two groups.RESULTS:The effective rate and clinical benefit rate of cisplatin group were respectively 73.91%(34/46)and 93.48%(43/46),while the effective rate and clinical benefit rate of cisplatin group were respectively 75.56%(34/45)and 93.33%(42/45);there were no statistical significance in differences in effective rate and clinical benefit rate between two groups(P>0.05).The incidences of hemoglobin reduction,electrolyte imbalance,kidney damage,nausea and vomiting in the cisplatin group were significantly higher than those in nedaplatin group,with statistically significant differences(P<0.05).The cost of chemotherapy alone in cisplatin group was significantly lower than that in nedaplatin group,with statistically significant differences(P<0.05);while there was no statistical significance in difference in total costs between two groups(P>0.05).CONCLUSIONS:The short-term efficacy and total cost of simultaneous proton and heavy ion radiotherapy of cisplatin and nedaplatin in the treatment of nasopharyngeal malignant tumor are equivalent,but nedaplatin has significantly fewer adverse drug reactions.

关 键 词：鼻咽恶性肿瘤 顺铂 奈达铂 质子重离子 疗效 

分 类 号：R979.1[医药卫生—药品]